Our Partners
DUHE Group
Exhibition Partner
Inner Mongolia Duhe Chuangyan Technology Development Co., Ltd. (“Duhe”) is a biotech company pioneering scalable, cost-efficient synthesis technologies for α-amanitin and other cyclic peptide toxins used as payloads in Antibody-Drug Conjugates (ADCs). Founded in 2019, Duhe has developed proprietary methods that significantly reduce synthesis steps, increase purity, and improve overall production economics. These innovations address major bottlenecks in the ADC field, particularly the limited supply and high cost of α-amanitin. In addition to toxin payloads, Duhe also synthesizes unnatural amino acids, peptide drugs, and other complex molecules for pharmaceutical applications. Backed by Chinese investors, the company employs 20 staff and is now actively engaging global biopharma partners to commercialize its platform.
Farmhispania
Innovation Partner
Farmhispania Group (FHG) is a CDMO at the forefront of research, development and commercialization of complex APIs, HPAPIs and cGMP advanced intermediates. With 2 multi-purpose cGMP and FDA inspected manufacturing plants in Spain (Barcelona and Zaragoza) – FHG is housing over 120+ reactors with a total capacity of 436 m3.
FHG differential technologies include: HPAPI manufacturing (synthesis and
fermentation), large scale HPLC (including HPAPI), large scale freeze drying, Flow
Chemistry and Biocatalysis.
FHG offers a complete array of services to support small, mid-sized Biotechs and Big
Pharma companies with their NCEs programs from its pre-clinical stages to NDA filing and commercialization.
Simris Biologics
Event Partner
At Simris, we are pioneering the next generation of ADC payloads to revolutionise cancer treatment. Our platform is built on the world’s largest cyanobacterial strain library and over two decades of deep scientific expertise.
Through our proprietary discovery and bioconjugation technologies, we are developing novel, IP-protected payloads with the potential to dramatically improve both the efficacy and safety of ADC therapeutics.
Our next-generation ADC payloads are designed using cyanobacterial toxin engineering, and are built to outperform conventional payloads in potency, safety, and selectivity
Sygnature Discovery
Exhibition Partner
Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature Discovery has delivered 56 novel pre-clinical and 31 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.